Our Mission
Inclusive and Open to Diversity,
Innovationoriented to Win Together
and Benefit the Mankind

Haihe Biopharma
Pioneering the Future
of Original
Oncology Drugs

Haihe Stories
Our Scientists

Haihe Mission

Our Mission and Purpose

Research and Development

More R&D Pipelines

Haihe Stories

Our Scientists

About Us
  • Established in


  • Headquartered in




  • China’s Leading





  • Specializing in the Discovery,

    Development, Production

    and Commercialization

    Innovative Oncology


  • Academician1



    Number of


    As of Nov.30,2020

  • Core Products

    in R&D Pipeline


  • Compounds in

    Clinical Research


R&D Field
Cancer Types Covered by the R&D Pipeline
Lung Cancer
Breast Cancer
Gastric Cancer
Nasopharyngeal Cancer
Strong, Innovation-driven R&D Capabilities
10 Compounds in the Pipeline
7 Compounds in clinical studies
50 Patent

from China and the Patent
Cooperation Treaty
6 Major New Drug Invention Projects under
the Major National Science and Technology Special Program
and 8 Projects in Shanghai’s Science and Technology
Innovation Action Plan
Rich and Balanced Product Line
Updated in October 2020
  • 10 compounds, including those in late clinical stage and pre-clinical stage
  • The compound targets in the late stage of development have been verified
  • Multiple potential best-in-class compounds are expected to be used in combination to treat major indications
Company Milestones

Haihe Biopharma is a leading innovation-driven biotechnology company in China. Focusing on the discovery, development, production and commercialization of innovative anti-tumor drugs, Haihe brings life-saving therapies to cancer patients worldwide.


    July 2020

    Haihe completed
    Series B funding worth
    1.2 billion yuan


    July 2020

    Haihe completed the reorganization of related group companies. Shanghai Haihe Pharmaceutical Research and Development Co Ltd acquired the stakes of Nuomaixi (Shanghai) Pharmaceutical Technology Co Ltd, and transferred the equities held by all shareholders to Shanghai Haihe Pharmaceutical Research and Development Co Ltd.


    December 2019

    Haihe established its US office


    October 2019

    Haihe’s Manufacturing Hub set foot in Taizhou Medical New & Hi-Tech Industrial Development Zone, with planned investment of 600 million yuan


    September 2019

    Haihe was recognized as Shanghai’s New & Hi-Tech Enterprise


    April 2019

    The investigational drug paclitaxel oral formulation RMX 3001's Phase III clinicaltrial, which enrolled patients with advanced gastric cancer, completed the first dosing


    February 2019

    Haihe completed Series A funding worth US$136.6 million


    January 2019

    The pivotal Phase IIb clinical trial of first-class innovative drug Lucitanib for patients with thymic cancer completed the enrollment of the first patient in China


    September 2018

    Haihe reached strategic cooperation agreements with Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Tigermed, Junshi Biosciences, 3D Medicines, and Jiuzhou Pharmaceutical


    March 2018

    Haihe Pharmaceutical merged with Nuomaixi Pharmaceutical to form Haihe Biopharma Co, Ltd.

I am glad that some research achievements in China in the field of oncology drugs have already been on par with global leaders. Especially in personalized research, China is carrying out projects concurrently with the world, and striving to be a leader in certain aspects.

Academician Jian Ding:
Make Good Drugs that Ordinary People Can Afford

(Xinmin Evening News,2020-11-11)

I often tell myself to work hard and seize every opportunity. I also often inspire my team to develop good drugs that ordinary people can afford, so that new drugs created by Chinese scientists will come onto the global stage as soon as possible.
News Center
Join Us
Let’s ride the wave of developing original innovative drugs in China. Haihe Biopharma aspires to become one of the companies that R&D professionals and outstanding managers have the strongest desire to join.
Follow Us
?2020 Shanghai Haihe Biopharma Research and Development Co., Ltd.
All Rights Reserved 滬ICP備12016151號